{"gene":"RAD54L","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":2003,"finding":"p53, hRAD51, and hRAD54 (RAD54L) co-immunoprecipitate and co-localize at endogenous levels in normal cells, with co-localization at DNA processing sites after DNA breaks. hRAD54 binds directly to the p53 C-terminus in vitro without a nucleic acid intermediate. Functionally, p53-dependent anti-recombinogenic activity was attributed to p53 binding to hRAD51, and the elevation in recombination upon p53 inactivation is dependent on the hRAD51 pathway, placing RAD54L in the p53-regulated HR pathway.","method":"Co-immunoprecipitation, co-localization (immunofluorescence), direct binding assay in vitro (GST pulldown), host cell reactivation assay for recombination","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (Co-IP, direct binding in vitro, functional recombination assay) in a single study","pmids":["12750285"],"is_preprint":false},{"year":2001,"finding":"Expression of a dominant-negative mutant hRAD54 in DNA-PK-deficient (SCID) cells created double-mutant cells with increased ionizing radiation sensitivity, reduced DSB repair, and numerous incomplete chromatid exchange aberrations compared to either single mutant alone. Single-mutant hRAD54 cells showed wild-type phenotype, indicating that HR (RAD54L-dependent) is not apparent for DSB repair unless the primary NHEJ pathway is non-functional. Additionally, DNA-PK-null cells were more resistant to mitomycin-C than wild-type, suggesting HR is more efficient for cross-link repair in the absence of NHEJ.","method":"Dominant-negative mutant expression in SCID cell lines, ionizing radiation sensitivity assays, pulsed-field gel electrophoresis for DSB repair, chromosome aberration analysis, mitomycin-C survival assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — clean genetic epistasis with multiple readouts (survival, DSB repair kinetics, chromosome aberrations) in defined mutant backgrounds","pmids":["11289143"],"is_preprint":false},{"year":2005,"finding":"Expression of dominant-negative mutant hRAD54 in SCID cells reversed the abnormal telomere elongation characteristic of SCID cells and significantly reduced recombination rates at telomeres (measured by CO-FISH). This paralleled the effect of restoring functional DNA-PKcs, establishing that telomere elongation in SCID cells results from interactions between homologous recombination (RAD54L-dependent) and DNA-PKcs activity.","method":"Dominant-negative mutant hRAD54 expression in SCID cells, telomere length measurement, chromosome orientation FISH (CO-FISH) to measure telomeric recombination rates","journal":"Mutation research","confidence":"Medium","confidence_rationale":"Tier 2 — direct functional assay with CO-FISH; single lab, two complementary genetic manipulations","pmids":["15975611"],"is_preprint":false},{"year":2015,"finding":"RAD54L was identified as an oncogene co-located on human chromosome 1p32-35.3 and required for choroid plexus carcinoma (CPC) initiation and progression in both mouse and human tumors. Cross-species genomic analysis identified RAD54L as gained in tumors, and functional experiments established its necessity for disease progression, distinct from its known DNA repair role.","method":"Cross-species genome-wide syntenic region analysis, functional knockdown in mouse CPC model and human CPC cell lines, genomic copy number analysis","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 — cross-species genomic + functional validation; oncogenic role defined by loss-of-function with disease phenotype","pmids":["25965574"],"is_preprint":false},{"year":2017,"finding":"CHEK1 (Checkpoint kinase 1) regulates RAD54L expression via regulation of RAD54L promoter activity in glioblastoma cells. CHEK1 knockdown reduced RAD54L expression, increased apoptosis when combined with radiotherapy, and CHEK1 inhibition attenuated tumor growth, placing RAD54L downstream of CHEK1 in a transcriptional regulatory axis that promotes radioresistance.","method":"siRNA knockdown of CHEK1, luciferase reporter assays for RAD54L promoter activity, clonogenic survival assays, in vitro and in vivo tumor growth assays","journal":"Translational oncology","confidence":"Medium","confidence_rationale":"Tier 2–3 — promoter reporter + KD with defined phenotypic readout; single lab","pmids":["29287241"],"is_preprint":false},{"year":2018,"finding":"CDC7 kinase regulates RAD54L expression by controlling RAD54L promoter activity in glioblastoma. CDC7 knockdown reduced RAD54L levels, attenuated radioresistance, and CDC7 inhibitor reduced tumor growth both in vitro and in vivo, establishing a CDC7→RAD54L transcriptional axis in GBM radioresistance.","method":"siRNA knockdown of CDC7, luciferase reporter assay for RAD54L promoter, clonogenic survival after irradiation, in vivo xenograft tumor growth","journal":"Translational oncology","confidence":"Medium","confidence_rationale":"Tier 2–3 — promoter reporter + KD with functional radioresistance phenotype; single lab","pmids":["29413763"],"is_preprint":false},{"year":2020,"finding":"E2F1 directly binds to the promoter region of RAD54L and transcriptionally regulates RAD54L expression in bladder cancer cells. RAD54L induced by E2F1 mediates repair of DNA double-strand breaks caused by mitomycin C via the homologous recombination repair pathway.","method":"ChIP assay demonstrating E2F1 binding to RAD54L promoter, gene expression analysis, siRNA knockdown, DNA damage repair assays with mitomycin C","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP establishing direct promoter binding + functional HR repair assay; single lab","pmids":["33261027"],"is_preprint":false},{"year":2021,"finding":"The CSC-related transcription factor Oct4 A transcriptionally regulates RAD54L expression in head and neck squamous cell carcinoma. Knockdown of Oct4 A led to downregulation of RAD54L (and PSMC3IP), resulting in reduced self-renewal capacity and partial radiosensitization. Knockdown of RAD54L itself also reduced self-renewal and clonogenic survival after irradiation, directly linking RAD54L to HR-mediated repair and the cancer stem cell phenotype.","method":"Oct4 A siRNA knockdown, RAD54L siRNA knockdown, clonogenic survival assays after irradiation, self-renewal (sphere formation) assays, gene expression analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with specific phenotypic readouts (clonogenic survival, self-renewal); single lab, multiple targets validated","pmids":["34079088"],"is_preprint":false},{"year":2022,"finding":"RAD51AP1 and RAD54L define two distinct RAD51-dependent HR sub-pathways that function downstream of RAD51 recombinase. Concomitant deletion of RAD51AP1 and RAD54L synergistically sensitizes human cancer cells to olaparib, mitomycin C, and hydroxyurea beyond either single deletion. The RAD54L paralog RAD54B compensates for RAD54L deficiency, but less extensively than RAD51AP1, delineating non-redundant compensatory sub-pathways.","method":"CRISPR/Cas9 double knockout of RAD51AP1 and RAD54L, drug sensitivity assays (olaparib, mitomycin C, hydroxyurea), genetic epistasis analysis","journal":"Frontiers in cell and developmental biology","confidence":"High","confidence_rationale":"Tier 2 — clean double KO epistasis with multiple drug agents; synthetic interaction clearly delineates pathway structure","pmids":["35652094"],"is_preprint":false},{"year":2022,"finding":"High RAD54L expression in bladder cancer promotes abnormal tumor cell proliferation by altering cell cycle progression and suppressing cellular senescence. RAD54L expression is associated with p53, p21, and pRB levels in bladder cancer tissue, suggesting RAD54L modulates cell cycle checkpoint pathways.","method":"RAD54L knockdown, cell cycle analysis by flow cytometry, senescence assays (SA-β-gal staining), Western blotting for p53/p21/pRB","journal":"Medical oncology","confidence":"Low","confidence_rationale":"Tier 3 — KD with phenotype but molecular connection to p53/p21/pRB is correlative rather than mechanistically established","pmids":["36071250"],"is_preprint":false},{"year":2024,"finding":"RAD54L restrains replication fork progression and functions as a fork remodeler in human cancer cell lines and non-transformed cells. RAD54L decelerates fork progression under replication stress and suppresses replication-associated ssDNA gaps. RAD54L functions in two distinct RAD51-mediated fork reversal pathways: (1) In the HLTF/SMARCAL1 pathway, RAD54L is critical but its branch migration activity is dispensable, placing it downstream of HLTF/SMARCAL1; (2) In the FBH1 pathway, RAD54L's branch migration activity is essential, and FBH1 engagement depends on concerted action with RAD54L. Loss of RAD54L prevents nascent strand degradation in BRCA1/2- and 53BP1-deficient cells.","method":"DNA fiber assays (fork progression, ssDNA gap analysis), genetic epistasis with HLTF/SMARCAL1/FBH1 knockouts, branch migration-deficient RAD54L mutant, nascent strand degradation assays in BRCA1/2- and 53BP1-deficient backgrounds","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (fiber assay, epistasis, separation-of-function mutant) clearly delineating two distinct pathway roles; replicated between cancer and non-transformed cells","pmids":["39315725"],"is_preprint":false},{"year":2024,"finding":"In a Fragile X repeat expansion mouse model, loss of Rad54l (alone) did not significantly affect CGG repeat expansion, establishing by genetic epistasis that RAD54L-dependent HR pathways are not required for microsatellite repeat expansion in this context.","method":"Rad54l knockout mouse embryonic stem cells, repeat expansion assay by Southern blot/PCR, genetic epistasis with Rad52, Rad54b, Pol θ","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 — preprint, single lab; negative result with epistasis value but limited mechanistic insight into RAD54L function","pmids":["39574643"],"is_preprint":true},{"year":2025,"finding":"RAD54L plays a protective role in the nucleolar DNA damage response (nDDR). Loss of RAD54L increases nucleolar R-loops and rDNA damage, causes defects in nucleolar structure, and enhances sensitivity to PARP inhibitors and RNA Pol I inhibitors. RAD54L was identified as an unexpected protective factor in rDNA surveillance via a boutique CRISPR-Cas9 synthetic lethal screen.","method":"CRISPR-Cas9 synthetic lethal screen of DNA repair factors with RNA Pol I inhibitors, RAD54L knockout cells, R-loop quantification (DRIP assay), rDNA damage assays, nucleolar structure analysis by microscopy","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR screen + KO validation with multiple readouts (R-loops, rDNA damage, nucleolar structure); preprint, single lab","pmids":["bio_10.1101_2025.01.20.633984"],"is_preprint":true},{"year":2025,"finding":"RAD54L is required for the resolution of long RAD51/MND1-containing filamentous structures that form during homology search after DSB induction in living human cells. Loss of RAD54L prevented the resolution of these filaments, which are highly dynamic and explore nuclear space. This places RAD54L functionally downstream of RAD51 filament formation, at the step of homology search completion and strand invasion.","method":"Live-cell imaging with GFP-MND1 to visualize homology search filaments in human cells, RAD54L siRNA/knockout, time-lapse microscopy of filament dynamics and resolution","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — direct live-cell visualization with loss-of-function; novel tool establishing RAD54L's role in filament resolution; preprint, single lab","pmids":["bio_10.1101_2025.03.01.640932"],"is_preprint":true},{"year":2026,"finding":"The transcription factor SOHLH2 transcriptionally activates RAD54L expression in non-small cell lung cancer. SOHLH2 overexpression promotes HR repair and radioresistance, while SOHLH2 knockdown suppresses these effects. Overexpression of RAD54L rescues the suppression of HR repair and radioresistance caused by SOHLH2 knockdown, establishing a SOHLH2→RAD54L transcriptional axis in NSCLC radioresistance.","method":"SOHLH2 knockdown and overexpression, RAD54L overexpression rescue experiments, chromatin immunoprecipitation (ChIP) for SOHLH2 binding to RAD54L promoter, HR repair assays, clonogenic survival after irradiation","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP + rescue experiment establishing epistasis; single lab with multiple functional readouts","pmids":["41535248"],"is_preprint":false}],"current_model":"RAD54L is a SWI2/SNF2-family DNA motor protein that functions downstream of RAD51 in homologous recombination (HR): it resolves RAD51/MND1 filaments during homology search, promotes strand invasion via branch migration, and operates in at least two distinct RAD51-mediated replication fork reversal pathways (HLTF/SMARCAL1- and FBH1-dependent) with different requirements for its branch migration activity; RAD54L also plays a protective role in nucleolar rDNA surveillance, interacts physically with p53 (via the p53 C-terminus) and participates in a network of transcriptional regulation by E2F1, CHEK1, CDC7, Oct4, and SOHLH2 that modulates HR-mediated DNA repair capacity and radioresistance in cancer cells."},"narrative":{"teleology":[{"year":2001,"claim":"The question of whether RAD54L-dependent HR contributes to DSB repair in mammalian cells was addressed by showing that dominant-negative RAD54L increases radiation sensitivity and chromosomal aberrations only when the primary NHEJ pathway (DNA-PKcs) is inactivated, establishing HR as a backup DSB repair route whose contribution is masked by NHEJ.","evidence":"Dominant-negative hRAD54 expression in SCID (DNA-PK-deficient) cells with IR sensitivity, PFGE, and chromosome aberration analysis","pmids":["11289143"],"confidence":"High","gaps":["Whether RAD54L enzymatic activity (ATPase/branch migration) is specifically required was not dissected","Contribution of RAD54L to HR in non-transformed human cells was not tested"]},{"year":2003,"claim":"The nature of RAD54L's interaction with p53 and RAD51 was clarified: RAD54L co-immunoprecipitates with both p53 and RAD51 at endogenous levels, binds p53's C-terminus directly in vitro, and co-localizes at DNA processing sites, placing RAD54L within the p53-regulated HR complex.","evidence":"Co-IP, GST pulldown for direct binding, immunofluorescence co-localization, and host-cell reactivation recombination assay in human cells","pmids":["12750285"],"confidence":"High","gaps":["Structural basis of the p53–RAD54L interaction is unknown","Functional consequence of disrupting the p53–RAD54L interaction specifically (vs. p53–RAD51) was not separated"]},{"year":2005,"claim":"RAD54L-dependent HR was shown to mediate the aberrant telomere elongation observed in SCID cells, extending RAD54L's functional scope beyond canonical DSB repair to telomere maintenance.","evidence":"Dominant-negative RAD54L in SCID cells with telomere length measurement and CO-FISH for telomeric recombination","pmids":["15975611"],"confidence":"Medium","gaps":["Whether RAD54L acts at telomeres in wild-type cells with functional DNA-PKcs is unknown","Mechanism by which HR elongates telomeres in SCID cells was not molecularly resolved"]},{"year":2015,"claim":"Beyond its repair role, RAD54L was identified as a potential oncogene gained in choroid plexus carcinoma, with functional knockdown demonstrating its requirement for CPC initiation and progression—expanding RAD54L's disease relevance beyond DNA repair deficiency.","evidence":"Cross-species syntenic genome analysis plus functional knockdown in mouse CPC model and human CPC cell lines","pmids":["25965574"],"confidence":"Medium","gaps":["Mechanism by which RAD54L promotes tumorigenesis (repair-dependent vs. repair-independent) was not resolved","Whether this oncogenic role extends to other tumor types was not determined"]},{"year":2017,"claim":"Upstream transcriptional control of RAD54L began to be mapped: CHEK1 and subsequently CDC7 were shown to regulate RAD54L promoter activity in glioblastoma, establishing kinase-to-transcription axes that modulate HR capacity and radioresistance.","evidence":"siRNA knockdown of CHEK1/CDC7, luciferase reporter assays for RAD54L promoter, clonogenic survival after IR, xenograft models","pmids":["29287241","29413763"],"confidence":"Medium","gaps":["Whether CHEK1 and CDC7 act on the same or distinct cis-elements in the RAD54L promoter is unknown","Direct transcription factor intermediaries between these kinases and the RAD54L promoter were not identified"]},{"year":2020,"claim":"E2F1 was shown to directly bind the RAD54L promoter and transcriptionally induce RAD54L expression, with the resulting RAD54L mediating HR repair of mitomycin C-induced DSBs in bladder cancer, providing the first direct transcription factor–promoter interaction driving RAD54L in cancer.","evidence":"ChIP for E2F1 at RAD54L promoter, siRNA knockdown, mitomycin C DNA damage repair assays in bladder cancer cells","pmids":["33261027"],"confidence":"Medium","gaps":["Whether E2F1 is the dominant transcriptional regulator of RAD54L or cooperates with CHEK1/CDC7-regulated factors is unclear","Chromatin context and epigenetic modulation of the RAD54L promoter were not examined"]},{"year":2022,"claim":"Genetic epistasis analysis using CRISPR double knockouts established that RAD54L and RAD51AP1 define two parallel, non-redundant HR sub-pathways downstream of RAD51, with concomitant loss producing synergistic sensitivity to olaparib, mitomycin C, and hydroxyurea.","evidence":"CRISPR/Cas9 double KO of RAD51AP1 and RAD54L in human cancer cells, multi-agent drug sensitivity assays","pmids":["35652094"],"confidence":"High","gaps":["Substrate or intermediate specificity distinguishing the two sub-pathways is not defined","Whether RAD54B fully substitutes for RAD54L in specific genomic contexts was not resolved"]},{"year":2024,"claim":"RAD54L was shown to function as a replication fork remodeler that restrains fork progression and suppresses ssDNA gaps under replication stress, acting in two mechanistically distinct RAD51-mediated fork reversal pathways—one with HLTF/SMARCAL1 (branch migration dispensable) and one with FBH1 (branch migration essential)—resolving a longstanding question about how RAD54L's ATPase and branch migration activities are differentially deployed.","evidence":"DNA fiber assays, genetic epistasis with HLTF/SMARCAL1/FBH1 KO, branch migration-deficient RAD54L mutant, nascent strand degradation in BRCA1/2- and 53BP1-deficient backgrounds","pmids":["39315725"],"confidence":"High","gaps":["Structural basis for differential engagement of RAD54L in the two fork reversal pathways is unknown","Whether the fork remodeling function is relevant in non-replicating or quiescent cells was not tested"]},{"year":2025,"claim":"Live-cell imaging directly visualized RAD54L's requirement for resolution of RAD51/MND1-containing filaments during homology search, placing RAD54L at the transition from homology search to strand invasion in living human cells.","evidence":"Live-cell imaging with GFP-MND1, RAD54L siRNA/knockout, time-lapse microscopy of filament dynamics (preprint)","pmids":["bio_10.1101_2025.03.01.640932"],"confidence":"Medium","gaps":["Whether RAD54L's ATPase or branch migration activity drives filament resolution is not distinguished","Awaits peer review and independent replication"]},{"year":2025,"claim":"A CRISPR synthetic lethal screen revealed an unexpected protective role for RAD54L in nucleolar rDNA surveillance: RAD54L loss increases nucleolar R-loops, rDNA damage, and sensitivity to PARP and RNA Pol I inhibitors, extending RAD54L function to the nucleolar DNA damage response.","evidence":"CRISPR-Cas9 screen with RNA Pol I inhibitors, RAD54L KO, DRIP for R-loops, rDNA damage and nucleolar structure assays (preprint)","pmids":["bio_10.1101_2025.01.20.633984"],"confidence":"Medium","gaps":["Whether RAD54L acts directly on rDNA or indirectly via general HR at the nucleolus is unclear","Awaits peer review and independent validation"]},{"year":2026,"claim":"SOHLH2 was identified as a transcriptional activator of RAD54L in NSCLC, with RAD54L overexpression fully rescuing HR repair and radioresistance upon SOHLH2 loss, confirming a direct SOHLH2→RAD54L transcriptional axis.","evidence":"ChIP for SOHLH2 at RAD54L promoter, rescue overexpression experiments, HR repair and clonogenic survival assays","pmids":["41535248"],"confidence":"Medium","gaps":["Whether SOHLH2 cooperates with E2F1 or other transcription factors at the RAD54L promoter is unknown","Relevance of the SOHLH2–RAD54L axis in non-malignant tissues is not examined"]},{"year":null,"claim":"Key unresolved questions include: the structural basis for RAD54L's differential engagement in fork reversal vs. DSB repair vs. nucleolar rDNA surveillance; whether RAD54L's repair-independent oncogenic function in CPC and other tumors depends on its ATPase/branch migration activities; and how the multiple transcriptional inputs (E2F1, CHEK1, CDC7, Oct4, SOHLH2) are integrated at the RAD54L promoter in physiological contexts.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of human RAD54L in complex with its substrates or partners","Repair-dependent vs. repair-independent oncogenic mechanisms not separated","Integrated promoter logic for RAD54L regulation across cell types not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[10]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[10,13]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[10,8]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,13]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[12]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,1,8,10,13]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[10]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[10]}],"complexes":[],"partners":["RAD51","TP53","RAD51AP1","MND1","HLTF","SMARCAL1","FBH1"],"other_free_text":[]},"mechanistic_narrative":"RAD54L is a SWI2/SNF2-family ATPase that functions downstream of RAD51 in homologous recombination, where it resolves RAD51/MND1-containing filaments during homology search, promotes strand invasion, and operates in two distinct RAD51-dependent replication fork reversal pathways—one HLTF/SMARCAL1-dependent (branch migration-dispensable) and one FBH1-dependent (branch migration-essential)—to restrain fork progression and suppress replication-associated ssDNA gaps [PMID:39315725, PMID:35652094]. RAD54L defines a non-redundant HR sub-pathway parallel to RAD51AP1, and its loss synergistically sensitizes cells to PARP inhibitors, mitomycin C, and hydroxyurea [PMID:35652094]. RAD54L physically interacts with p53 via the p53 C-terminus and co-localizes with RAD51 at DNA damage sites, integrating HR with p53-mediated anti-recombinogenic control [PMID:12750285]. Its expression is transcriptionally regulated by E2F1, CHEK1, CDC7, Oct4, and SOHLH2, linking HR repair capacity to radioresistance in multiple cancer types [PMID:33261027, PMID:29287241, PMID:41535248]."},"prefetch_data":{"uniprot":{"accession":"Q92698","full_name":"DNA repair and recombination protein RAD54-like","aliases":["RAD54 homolog","hHR54","hRAD54"],"length_aa":747,"mass_kda":84.4,"function":"Multifunctional ATPase that plays a role in homologous recombination (HR) which is a major pathway for repairing DNA double-strand breaks (DSBs), single-stranded DNA (ssDNA) gaps, and stalled or collapsed replication forks (PubMed:11459989, PubMed:12205100, PubMed:24798879, PubMed:27264870, PubMed:32457312, PubMed:9774452). Acts as a molecular motor during the homology search and guides RAD51 ssDNA along a donor dsDNA thereby changing the homology search from the diffusion-based mechanism to a motor-guided mechanism. Also plays an essential role in RAD51-mediated synaptic complex formation which consists of three strands encased in a protein filament formed once homology is recognized. Once DNA strand exchange occured, dissociates RAD51 from nucleoprotein filaments formed on dsDNA (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q92698/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RAD54L","classification":"Not Classified","n_dependent_lines":70,"n_total_lines":1208,"dependency_fraction":0.057947019867549666},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RAD54L","total_profiled":1310},"omim":[{"mim_id":"605027","title":"LYMPHOMA, NON-HODGKIN, FAMILIAL","url":"https://www.omim.org/entry/605027"},{"mim_id":"603615","title":"RAD54-LIKE; RAD54L","url":"https://www.omim.org/entry/603615"},{"mim_id":"601310","title":"CYTOCHROME P450, SUBFAMILY IVA, POLYPEPTIDE 11; CYP4A11","url":"https://www.omim.org/entry/601310"},{"mim_id":"600392","title":"RAD52 HOMOLOG, DNA REPAIR PROTEIN; RAD52","url":"https://www.omim.org/entry/600392"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":8.2},{"tissue":"lymphoid tissue","ntpm":14.3},{"tissue":"testis","ntpm":11.8}],"url":"https://www.proteinatlas.org/search/RAD54L"},"hgnc":{"alias_symbol":["hHR54","hRAD54","RAD54A"],"prev_symbol":[]},"alphafold":{"accession":"Q92698","domains":[{"cath_id":"3.40.50.10810","chopping":"149-343","consensus_level":"high","plddt":88.0756,"start":149,"end":343},{"cath_id":"1.20.120.850","chopping":"419-495_656-667","consensus_level":"medium","plddt":84.0352,"start":419,"end":667}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92698","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92698-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92698-F1-predicted_aligned_error_v6.png","plddt_mean":80.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RAD54L","jax_strain_url":"https://www.jax.org/strain/search?query=RAD54L"},"sequence":{"accession":"Q92698","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92698.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92698/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92698"}},"corpus_meta":[{"pmid":"12750285","id":"PMC_12750285","title":"p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12750285","citation_count":143,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16520463","id":"PMC_16520463","title":"Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.","date":"2006","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16520463","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25965574","id":"PMC_25965574","title":"Cross-Species Genomics Identifies TAF12, NFYC, and RAD54L as Choroid Plexus Carcinoma Oncogenes.","date":"2015","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/25965574","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34079088","id":"PMC_34079088","title":"Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34079088","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10326867","id":"PMC_10326867","title":"Search for mutations of the hRAD54 gene in sporadic meningiomas with deletion at 1p32.","date":"1999","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/10326867","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33261027","id":"PMC_33261027","title":"E2F1 Promotes Progression of Bladder Cancer by Modulating RAD54L Involved in Homologous Recombination Repair.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33261027","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12614485","id":"PMC_12614485","title":"Implications of a RAD54L polymorphism (2290C/T) in human meningiomas as a risk factor and/or a genetic marker.","date":"2003","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12614485","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35652094","id":"PMC_35652094","title":"RAD51AP1 and RAD54L Can Underpin Two Distinct RAD51-Dependent Routes of DNA Damage Repair via Homologous Recombination.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35652094","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10640146","id":"PMC_10640146","title":"hRAD54 gene and 1p high-resolution deletion-mapping analyses in oligodendrogliomas.","date":"2000","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10640146","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11289143","id":"PMC_11289143","title":"Severe combined immunodeficient cells expressing mutant hRAD54 exhibit a marked DNA double-strand break repair and error-prone chromosome repair defect.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11289143","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29413763","id":"PMC_29413763","title":"CDC7-dependent transcriptional regulation of RAD54L is essential for tumorigenicity and radio-resistance of glioblastoma.","date":"2018","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29413763","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36071250","id":"PMC_36071250","title":"Rad54L promotes bladder cancer progression by regulating cell cycle and cell senescence.","date":"2022","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36071250","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29287241","id":"PMC_29287241","title":"Serine/Threonine Kinase CHEK1-Dependent Transcriptional Regulation of RAD54L Promotes Proliferation and Radio Resistance in Glioblastoma.","date":"2017","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29287241","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39315725","id":"PMC_39315725","title":"Disparate requirements for RAD54L in replication fork reversal.","date":"2024","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/39315725","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37719938","id":"PMC_37719938","title":"Pan-Cancer Analysis of Oncogenic Role of RAD54L and Experimental Validation in Hepatocellular Carcinoma.","date":"2023","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/37719938","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18203022","id":"PMC_18203022","title":"Germline mutations in RAD51, RAD51AP1, RAD51B, RAD51C,RAD51D, RAD52 and RAD54L do not contribute to familial chronic lymphocytic leukemia.","date":"2008","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/18203022","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37071224","id":"PMC_37071224","title":"RAD54L promotes progression of hepatocellular carcinoma via the homologous recombination repair pathway.","date":"2023","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/37071224","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33628633","id":"PMC_33628633","title":"Homologous recombination repair rathway and RAD54L in early-stage lung adenocarcinoma.","date":"2021","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/33628633","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21637572","id":"PMC_21637572","title":"Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia.","date":"2010","source":"Genetics and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21637572","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32758138","id":"PMC_32758138","title":"Germline RAD54L with somatic POLE defect implicated in Hypermutation phenotype: case report.","date":"2020","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/32758138","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15975611","id":"PMC_15975611","title":"Shortened telomeres in murine scid cells expressing mutant hRAD54 coincide with reduction in recombination at telomeres.","date":"2005","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/15975611","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34169999","id":"PMC_34169999","title":"Association of MTHFR, MTRR and RAD54L Gene Variations with Meningioma and Correlation with Tumor's Histopathological Characteristics on Turkish Cohort.","date":"2021","source":"Turkish neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/34169999","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37546955","id":"PMC_37546955","title":"Disparate requirements for RAD54L in replication fork reversal.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37546955","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40730084","id":"PMC_40730084","title":"Porcine reproductive and respiratory syndrome virus downregulates the circ-107191/miR-34c/RAD54L axis to promote testicular cell apoptosis via impaired homologous recombination repair.","date":"2025","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/40730084","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41185726","id":"PMC_41185726","title":"A Case of Metastatic Castration-Resistant Prostate Cancer With RAD54L Mutation Responding to Niraparib.","date":"2025","source":"IJU case reports","url":"https://pubmed.ncbi.nlm.nih.gov/41185726","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39574643","id":"PMC_39574643","title":"Repeat expansion in a Fragile X model is independent of double strand break repair mediated by Pol θ, Rad52, Rad54l or Rad54b.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39574643","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38279717","id":"PMC_38279717","title":"Novel Association of RAD54L Mutation with Müllerian Clear Cell Carcinoma of the Male Urethra: New Insights Regarding the Molecular Mechanisms of a Rare Tumour.","date":"2024","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/38279717","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41535248","id":"PMC_41535248","title":"SOHLH2-RAD54L axis induces radioresistance by promoting homologous recombination repair in non-small cell lung cancer.","date":"2026","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/41535248","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.01.20.633984","title":"Local nucleolar surveillance mechanisms maintain rDNA stability","date":"2025-01-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.20.633984","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.03.01.640932","title":"Visualizing homology search in living cells","date":"2025-03-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.01.640932","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.08.27.25333852","title":"Ultrarare Variants in DNA Damage Repair and Mitochondrial Genes in Pediatric Acute-Onset Neuropsychiatric Syndrome and Acute Behavioral Regression in Neurodevelopmental Disorders","date":"2025-08-27","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.27.25333852","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"17081983","id":"PMC_17081983","title":"Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17081983","citation_count":2861,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3658675","id":"PMC_3658675","title":"RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression.","date":"1987","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/3658675","citation_count":2261,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21252315","id":"PMC_21252315","title":"DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.","date":"2011","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21252315","citation_count":1392,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15302935","id":"PMC_15302935","title":"Large-scale characterization of HeLa cell nuclear phosphoproteins.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15302935","citation_count":1159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20211137","id":"PMC_20211137","title":"Distinct factors control histone variant H3.3 localization at specific genomic regions.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/20211137","citation_count":1038,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15635413","id":"PMC_15635413","title":"Nucleolar proteome dynamics.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15635413","citation_count":934,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21719641","id":"PMC_21719641","title":"Altered telomeres in tumors with ATRX and DAXX mutations.","date":"2011","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21719641","citation_count":877,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15772651","id":"PMC_15772651","title":"The DNA sequence of the human X chromosome.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15772651","citation_count":816,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20651253","id":"PMC_20651253","title":"Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20651253","citation_count":674,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20504901","id":"PMC_20504901","title":"The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3.","date":"2010","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/20504901","citation_count":541,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22829774","id":"PMC_22829774","title":"Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22829774","citation_count":508,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7697714","id":"PMC_7697714","title":"Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome).","date":"1995","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7697714","citation_count":494,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22869205","id":"PMC_22869205","title":"Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.","date":"2012","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/22869205","citation_count":463,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10742099","id":"PMC_10742099","title":"Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation.","date":"2000","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10742099","citation_count":386,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22416102","id":"PMC_22416102","title":"Association of age at diagnosis and genetic mutations in patients with neuroblastoma.","date":"2012","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/22416102","citation_count":351,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24148618","id":"PMC_24148618","title":"Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.","date":"2013","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/24148618","citation_count":348,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20110566","id":"PMC_20110566","title":"ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells.","date":"2010","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/20110566","citation_count":338,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21029860","id":"PMC_21029860","title":"ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21029860","citation_count":337,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15762,"output_tokens":3136,"usd":0.047163},"stage2":{"model":"claude-opus-4-6","input_tokens":6479,"output_tokens":2995,"usd":0.160905},"total_usd":0.470409,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":28589,"output_tokens":5204,"usd":0.081914},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":7857,"output_tokens":3240,"usd":0.180427}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"p53 directly binds to the hRAD54 (RAD54L) C-terminus in vitro without a nucleic acid intermediate, and p53, hRAD51, and hRAD54 coimmunoprecipitate and colocalize at endogenous levels in normal cells at presumed DNA processing sites after DNA break induction; p53's antirecombinogenic activity is dependent on the hRAD51 pathway, placing RAD54L in a p53-regulated homologous recombination axis.\",\n      \"method\": \"Co-immunoprecipitation, colocalization by immunofluorescence, in vitro direct binding assay, host cell reactivation recombination assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct in vitro binding assay plus reciprocal Co-IP plus functional recombination assay, multiple orthogonal methods in one study\",\n      \"pmids\": [\"12750285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Expression of a dominant-negative mutant hRAD54 in DNA-PK-deficient (SCID) cells increases ionizing radiation sensitivity and decreases DSB repair compared to either single mutant, demonstrating that HR (RAD54L-dependent) and NHEJ (DNA-PK-dependent) are two independent DSB repair pathways in mammalian cells; mutant hRAD54 cells alone show a wild-type phenotype, indicating HR is a secondary pathway when NHEJ is functional.\",\n      \"method\": \"Dominant-negative expression of mutant hRAD54 in DNA-PK-deficient SCID cells, clonogenic survival, neutral comet assay for DSB repair, chromosome aberration analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with defined phenotypic readout (survival, DSB repair, chromosome aberrations), multiple orthogonal assays\",\n      \"pmids\": [\"11289143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Mutant hRAD54 expressed in SCID cells reverses telomere elongation and reduces recombination rates at telomeres (measured by CO-FISH), indicating that RAD54L-mediated homologous recombination contributes to telomere length regulation, with effects equivalent to restoring functional DNA-PKcs.\",\n      \"method\": \"Dominant-negative hRAD54 expression in SCID cells, chromosome orientation FISH (CO-FISH) to measure telomere recombination rates, telomere length measurement\",\n      \"journal\": \"Mutation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization/functional experiment with CO-FISH, single lab, two orthogonal readouts\",\n      \"pmids\": [\"15975611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RAD54L and RAD51AP1 define two distinct, partially redundant RAD51-dependent sub-pathways of homologous recombination; concomitant deletion of RAD51AP1 and RAD54L further sensitizes human cancer cells to olaparib, mitomycin C, and hydroxyurea beyond either single deletion, and the RAD54L paralog RAD54B can partially compensate for RAD54L deficiency.\",\n      \"method\": \"CRISPR/siRNA double-knockout of RAD51AP1 and RAD54L in human cancer cell lines, clonogenic survival assays with olaparib, MMC, and hydroxyurea\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic epistasis (double-KO) with multiple DNA damage agents, defined cellular phenotype and pathway placement\",\n      \"pmids\": [\"35652094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RAD54L functions as a DNA motor/fork remodeler that restrains replication fork progression and catalyzes replication fork reversal; it operates in two distinct RAD51-mediated fork reversal pathways: (1) downstream of HLTF/SMARCAL1 where its branch migration activity is dispensable, and (2) in the FBH1 pathway where its branch migration activity is essential and FBH1 engagement depends on RAD54L's concerted action; loss of RAD54L prevents nascent strand degradation in BRCA1/2- and 53BP1-deficient cells.\",\n      \"method\": \"RAD54L knockdown/knockout in human cancer and non-transformed cell lines, DNA fiber assay for fork speed, S1 nuclease assay for ssDNA gaps, branch-migration mutant rescue experiments, epistasis with HLTF/SMARCAL1/FBH1 knockdowns\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including in vitro branch migration data, genetic epistasis with multiple pathway components, functional mutant analysis\",\n      \"pmids\": [\"39315725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"E2F1 directly binds to the promoter region of RAD54L and transcriptionally regulates RAD54L expression, which in turn mediates homologous recombination repair of DNA double-strand breaks induced by mitomycin C in bladder cancer cells; knockdown of RAD54L reduces HR repair capacity.\",\n      \"method\": \"ChIP assay (E2F1 binding to RAD54L promoter), luciferase reporter assay, siRNA knockdown, gamma-H2AX foci assay after MMC treatment\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter assay plus functional HR readout, single lab, moderate evidence\",\n      \"pmids\": [\"33261027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CHEK1 transcriptionally regulates RAD54L expression via RAD54L promoter activity, and this axis promotes radioresistance in glioblastoma cells; CHEK1 knockdown reduces RAD54L expression and increases apoptosis after radiotherapy.\",\n      \"method\": \"siRNA knockdown of CHEK1, RAD54L promoter-luciferase reporter assay, clonogenic survival, apoptosis assay after irradiation\",\n      \"journal\": \"Translational oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter reporter assay plus functional radioresistance readout, single lab\",\n      \"pmids\": [\"29287241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CDC7 kinase regulates RAD54L expression via RAD54L promoter activity, promoting radioresistance in glioblastoma; CDC7 knockdown reduces RAD54L-mediated HR repair and sensitizes GBM cells to radiotherapy.\",\n      \"method\": \"siRNA knockdown of CDC7, RAD54L promoter-luciferase reporter assay, clonogenic survival after irradiation, in vivo tumor xenograft\",\n      \"journal\": \"Translational oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter reporter assay plus in vivo validation, single lab\",\n      \"pmids\": [\"29413763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Oct4 (isoform A) transcriptionally regulates RAD54L (and PSMC3IP), and knockdown of RAD54L reduces HNSCC self-renewal capacity and clonogenic survival after irradiation, linking RAD54L to both HR-mediated DNA repair and the cancer stem cell phenotype; PARP inhibitor olaparib selectively radiosensitizes Oct4 A-knockout cells, suggesting synthetic lethality in an HR-compromised context.\",\n      \"method\": \"siRNA/shRNA knockdown of Oct4A and RAD54L, clonogenic survival assay, gamma-H2AX foci, sphere-formation self-renewal assay, olaparib radiosensitization assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with defined cellular phenotypes, multiple readouts, single lab\",\n      \"pmids\": [\"34079088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RAD54L plays a protective role in the nucleolar DNA damage response (nDDR); loss of RAD54L increases nucleolar R-loops and rDNA damage, causes defects in nucleolar structure, and enhances sensitivity to PARP inhibitors and RNA Pol I inhibitors, indicating RAD54L functions as a DNA translocase required for rDNA stability.\",\n      \"method\": \"CRISPR-Cas9 synthetic lethal screen of DNA repair factors with RNA Pol I inhibitors, RAD54L knockout, R-loop immunofluorescence, nucleolar structure imaging, drug sensitivity assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO with multiple orthogonal readouts, preprint not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.01.20.633984\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RAD54L is required for resolution of RAD51/MND1 filamentous structures that form during homology search after DSB formation; loss of RAD54L prevents dissolution of these filaments in living human cells, consistent with RAD54L's role in facilitating RAD51-driven strand invasion.\",\n      \"method\": \"Live-cell imaging of GFP-MND1 filaments in human cells, RAD54L knockdown/knockout, time-lapse microscopy\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct live-cell visualization with functional genetic perturbation, preprint\",\n      \"pmids\": [\"bio_10.1101_2025.03.01.640932\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"SOHLH2 transcriptionally activates RAD54L expression by binding its promoter, thereby promoting HR repair and radioresistance in non-small cell lung cancer; RAD54L overexpression rescues HR repair and radioresistance suppressed by SOHLH2 knockdown.\",\n      \"method\": \"siRNA knockdown of SOHLH2 and RAD54L, RAD54L overexpression rescue, gamma-H2AX foci assay, clonogenic survival after irradiation, ChIP/luciferase reporter for SOHLH2 binding to RAD54L promoter\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — rescue experiment plus promoter assay plus functional readout, single lab\",\n      \"pmids\": [\"41535248\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RAD54L is a SWI2/SNF2-family DNA motor protein that functions downstream of RAD51 in homologous recombination (HR) by facilitating strand invasion and branch migration, directly binds p53 and forms a complex with RAD51 to modulate HR, acts as a replication fork remodeler in two distinct RAD51-mediated fork reversal pathways (operating downstream of HLTF/SMARCAL1 via a branch-migration-independent mechanism and cooperating with FBH1 via its branch migration activity), participates in nucleolar rDNA surveillance by suppressing R-loops, and is transcriptionally regulated by multiple upstream factors including p53, E2F1, CHEK1, CDC7, Oct4, and SOHLH2, collectively placing it as a central HR effector whose loss compromises DSB repair, fork protection, and genome stability.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEEP papers.\n\n**CLASSIFICATION:**\n\nRetrieved papers:\n- [1] PMID:12750285 — KEEP (p53 interacts with hRAD51 and hRAD54/RAD54L, mechanistic)\n- [2] PMID:16520463 — EXCLUDE (SNP survival analysis, no mechanism)\n- [3] PMID:25965574 — KEEP (RAD54L identified as oncogene in CPC, functional validation)\n- [4] PMID:34079088 — KEEP (Oct4 regulates RAD54L transcriptionally, HR repair)\n- [5] PMID:10326867 — EXCLUDE (mutation screening, no mechanism)\n- [6] PMID:33261027 — KEEP (E2F1 transcriptionally regulates RAD54L)\n- [7] PMID:12614485 — EXCLUDE (SNP association, no mechanism)\n- [8] PMID:35652094 — KEEP (RAD51AP1 and RAD54L in distinct HR sub-pathways)\n- [9] PMID:10640146 — EXCLUDE (mutation screening, no mechanism)\n- [10] PMID:11289143 — KEEP (dominant mutant hRAD54 in SCID cells, DSB repair role)\n- [11] PMID:29413763 — KEEP (CDC7 regulates RAD54L promoter activity)\n- [12] PMID:36071250 — KEEP (RAD54L affects cell cycle and senescence, p53/p21/pRB association)\n- [13] PMID:29287241 — KEEP (CHEK1 regulates RAD54L expression)\n- [14] PMID:39315725 — KEEP (RAD54L in replication fork reversal, two pathways)\n- [15] PMID:37719938 — EXCLUDE (pan-cancer bioinformatics + basic proliferation/migration assays, limited mechanism)\n- [16] PMID:18203022 — EXCLUDE (germline mutation screening, no mechanism)\n- [17] PMID:37071224 — EXCLUDE (primarily expression/IHC correlation)\n- [18] PMID:33628633 — EXCLUDE (expression/survival analysis)\n- [19] PMID:21637572 — EXCLUDE (SNP association, no mechanism)\n- [20] PMID:32758138 — EXCLUDE (case report, no mechanism)\n- [21] PMID:15975611 — KEEP (mutant hRAD54 in telomere recombination)\n- [22] PMID:34169999 — EXCLUDE (SNP association, no mechanism)\n- [23] PMID:37546955 — KEEP (preprint version of PMID:39315725, same study)\n- [24] PMID:40730084 — EXCLUDE (case B: circRNA axis paper, alt-locus product involvement)\n- [25] PMID:41185726 — EXCLUDE (clinical case report)\n- [26] PMID:39574643 — KEEP (Rad54l in repeat expansion/DSBR, epistasis)\n- [27] PMID:38279717 — EXCLUDE (case report)\n- [28] PMID:41535248 — KEEP (SOHLH2 transcriptionally activates RAD54L)\n- [29] bio_10.1101_2025.01.20.633984 — KEEP (RAD54L in nucleolar DDR, CRISPR screen)\n- [30] bio_10.1101_2025.03.01.640932 — KEEP (RAD54L resolves MND1/RAD51 filaments in homology search)\n- [31] bio_10.1101_2025.08.27.25333852 — EXCLUDE (variant association study, no mechanism)\n\nGene2pubmed papers: All appear to be about ATRX, DAXX, or large-scale proteomics — EXCLUDE (alias collision or unrelated).\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"p53, hRAD51, and hRAD54 (RAD54L) co-immunoprecipitate and co-localize at endogenous levels in normal cells, with co-localization at DNA processing sites after DNA breaks. hRAD54 binds directly to the p53 C-terminus in vitro without a nucleic acid intermediate. Functionally, p53-dependent anti-recombinogenic activity was attributed to p53 binding to hRAD51, and the elevation in recombination upon p53 inactivation is dependent on the hRAD51 pathway, placing RAD54L in the p53-regulated HR pathway.\",\n      \"method\": \"Co-immunoprecipitation, co-localization (immunofluorescence), direct binding assay in vitro (GST pulldown), host cell reactivation assay for recombination\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (Co-IP, direct binding in vitro, functional recombination assay) in a single study\",\n      \"pmids\": [\"12750285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Expression of a dominant-negative mutant hRAD54 in DNA-PK-deficient (SCID) cells created double-mutant cells with increased ionizing radiation sensitivity, reduced DSB repair, and numerous incomplete chromatid exchange aberrations compared to either single mutant alone. Single-mutant hRAD54 cells showed wild-type phenotype, indicating that HR (RAD54L-dependent) is not apparent for DSB repair unless the primary NHEJ pathway is non-functional. Additionally, DNA-PK-null cells were more resistant to mitomycin-C than wild-type, suggesting HR is more efficient for cross-link repair in the absence of NHEJ.\",\n      \"method\": \"Dominant-negative mutant expression in SCID cell lines, ionizing radiation sensitivity assays, pulsed-field gel electrophoresis for DSB repair, chromosome aberration analysis, mitomycin-C survival assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic epistasis with multiple readouts (survival, DSB repair kinetics, chromosome aberrations) in defined mutant backgrounds\",\n      \"pmids\": [\"11289143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Expression of dominant-negative mutant hRAD54 in SCID cells reversed the abnormal telomere elongation characteristic of SCID cells and significantly reduced recombination rates at telomeres (measured by CO-FISH). This paralleled the effect of restoring functional DNA-PKcs, establishing that telomere elongation in SCID cells results from interactions between homologous recombination (RAD54L-dependent) and DNA-PKcs activity.\",\n      \"method\": \"Dominant-negative mutant hRAD54 expression in SCID cells, telomere length measurement, chromosome orientation FISH (CO-FISH) to measure telomeric recombination rates\",\n      \"journal\": \"Mutation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay with CO-FISH; single lab, two complementary genetic manipulations\",\n      \"pmids\": [\"15975611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RAD54L was identified as an oncogene co-located on human chromosome 1p32-35.3 and required for choroid plexus carcinoma (CPC) initiation and progression in both mouse and human tumors. Cross-species genomic analysis identified RAD54L as gained in tumors, and functional experiments established its necessity for disease progression, distinct from its known DNA repair role.\",\n      \"method\": \"Cross-species genome-wide syntenic region analysis, functional knockdown in mouse CPC model and human CPC cell lines, genomic copy number analysis\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cross-species genomic + functional validation; oncogenic role defined by loss-of-function with disease phenotype\",\n      \"pmids\": [\"25965574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CHEK1 (Checkpoint kinase 1) regulates RAD54L expression via regulation of RAD54L promoter activity in glioblastoma cells. CHEK1 knockdown reduced RAD54L expression, increased apoptosis when combined with radiotherapy, and CHEK1 inhibition attenuated tumor growth, placing RAD54L downstream of CHEK1 in a transcriptional regulatory axis that promotes radioresistance.\",\n      \"method\": \"siRNA knockdown of CHEK1, luciferase reporter assays for RAD54L promoter activity, clonogenic survival assays, in vitro and in vivo tumor growth assays\",\n      \"journal\": \"Translational oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — promoter reporter + KD with defined phenotypic readout; single lab\",\n      \"pmids\": [\"29287241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CDC7 kinase regulates RAD54L expression by controlling RAD54L promoter activity in glioblastoma. CDC7 knockdown reduced RAD54L levels, attenuated radioresistance, and CDC7 inhibitor reduced tumor growth both in vitro and in vivo, establishing a CDC7→RAD54L transcriptional axis in GBM radioresistance.\",\n      \"method\": \"siRNA knockdown of CDC7, luciferase reporter assay for RAD54L promoter, clonogenic survival after irradiation, in vivo xenograft tumor growth\",\n      \"journal\": \"Translational oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — promoter reporter + KD with functional radioresistance phenotype; single lab\",\n      \"pmids\": [\"29413763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"E2F1 directly binds to the promoter region of RAD54L and transcriptionally regulates RAD54L expression in bladder cancer cells. RAD54L induced by E2F1 mediates repair of DNA double-strand breaks caused by mitomycin C via the homologous recombination repair pathway.\",\n      \"method\": \"ChIP assay demonstrating E2F1 binding to RAD54L promoter, gene expression analysis, siRNA knockdown, DNA damage repair assays with mitomycin C\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP establishing direct promoter binding + functional HR repair assay; single lab\",\n      \"pmids\": [\"33261027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The CSC-related transcription factor Oct4 A transcriptionally regulates RAD54L expression in head and neck squamous cell carcinoma. Knockdown of Oct4 A led to downregulation of RAD54L (and PSMC3IP), resulting in reduced self-renewal capacity and partial radiosensitization. Knockdown of RAD54L itself also reduced self-renewal and clonogenic survival after irradiation, directly linking RAD54L to HR-mediated repair and the cancer stem cell phenotype.\",\n      \"method\": \"Oct4 A siRNA knockdown, RAD54L siRNA knockdown, clonogenic survival assays after irradiation, self-renewal (sphere formation) assays, gene expression analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with specific phenotypic readouts (clonogenic survival, self-renewal); single lab, multiple targets validated\",\n      \"pmids\": [\"34079088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RAD51AP1 and RAD54L define two distinct RAD51-dependent HR sub-pathways that function downstream of RAD51 recombinase. Concomitant deletion of RAD51AP1 and RAD54L synergistically sensitizes human cancer cells to olaparib, mitomycin C, and hydroxyurea beyond either single deletion. The RAD54L paralog RAD54B compensates for RAD54L deficiency, but less extensively than RAD51AP1, delineating non-redundant compensatory sub-pathways.\",\n      \"method\": \"CRISPR/Cas9 double knockout of RAD51AP1 and RAD54L, drug sensitivity assays (olaparib, mitomycin C, hydroxyurea), genetic epistasis analysis\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean double KO epistasis with multiple drug agents; synthetic interaction clearly delineates pathway structure\",\n      \"pmids\": [\"35652094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"High RAD54L expression in bladder cancer promotes abnormal tumor cell proliferation by altering cell cycle progression and suppressing cellular senescence. RAD54L expression is associated with p53, p21, and pRB levels in bladder cancer tissue, suggesting RAD54L modulates cell cycle checkpoint pathways.\",\n      \"method\": \"RAD54L knockdown, cell cycle analysis by flow cytometry, senescence assays (SA-β-gal staining), Western blotting for p53/p21/pRB\",\n      \"journal\": \"Medical oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — KD with phenotype but molecular connection to p53/p21/pRB is correlative rather than mechanistically established\",\n      \"pmids\": [\"36071250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RAD54L restrains replication fork progression and functions as a fork remodeler in human cancer cell lines and non-transformed cells. RAD54L decelerates fork progression under replication stress and suppresses replication-associated ssDNA gaps. RAD54L functions in two distinct RAD51-mediated fork reversal pathways: (1) In the HLTF/SMARCAL1 pathway, RAD54L is critical but its branch migration activity is dispensable, placing it downstream of HLTF/SMARCAL1; (2) In the FBH1 pathway, RAD54L's branch migration activity is essential, and FBH1 engagement depends on concerted action with RAD54L. Loss of RAD54L prevents nascent strand degradation in BRCA1/2- and 53BP1-deficient cells.\",\n      \"method\": \"DNA fiber assays (fork progression, ssDNA gap analysis), genetic epistasis with HLTF/SMARCAL1/FBH1 knockouts, branch migration-deficient RAD54L mutant, nascent strand degradation assays in BRCA1/2- and 53BP1-deficient backgrounds\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (fiber assay, epistasis, separation-of-function mutant) clearly delineating two distinct pathway roles; replicated between cancer and non-transformed cells\",\n      \"pmids\": [\"39315725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In a Fragile X repeat expansion mouse model, loss of Rad54l (alone) did not significantly affect CGG repeat expansion, establishing by genetic epistasis that RAD54L-dependent HR pathways are not required for microsatellite repeat expansion in this context.\",\n      \"method\": \"Rad54l knockout mouse embryonic stem cells, repeat expansion assay by Southern blot/PCR, genetic epistasis with Rad52, Rad54b, Pol θ\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — preprint, single lab; negative result with epistasis value but limited mechanistic insight into RAD54L function\",\n      \"pmids\": [\"39574643\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RAD54L plays a protective role in the nucleolar DNA damage response (nDDR). Loss of RAD54L increases nucleolar R-loops and rDNA damage, causes defects in nucleolar structure, and enhances sensitivity to PARP inhibitors and RNA Pol I inhibitors. RAD54L was identified as an unexpected protective factor in rDNA surveillance via a boutique CRISPR-Cas9 synthetic lethal screen.\",\n      \"method\": \"CRISPR-Cas9 synthetic lethal screen of DNA repair factors with RNA Pol I inhibitors, RAD54L knockout cells, R-loop quantification (DRIP assay), rDNA damage assays, nucleolar structure analysis by microscopy\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR screen + KO validation with multiple readouts (R-loops, rDNA damage, nucleolar structure); preprint, single lab\",\n      \"pmids\": [\"bio_10.1101_2025.01.20.633984\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RAD54L is required for the resolution of long RAD51/MND1-containing filamentous structures that form during homology search after DSB induction in living human cells. Loss of RAD54L prevented the resolution of these filaments, which are highly dynamic and explore nuclear space. This places RAD54L functionally downstream of RAD51 filament formation, at the step of homology search completion and strand invasion.\",\n      \"method\": \"Live-cell imaging with GFP-MND1 to visualize homology search filaments in human cells, RAD54L siRNA/knockout, time-lapse microscopy of filament dynamics and resolution\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct live-cell visualization with loss-of-function; novel tool establishing RAD54L's role in filament resolution; preprint, single lab\",\n      \"pmids\": [\"bio_10.1101_2025.03.01.640932\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"The transcription factor SOHLH2 transcriptionally activates RAD54L expression in non-small cell lung cancer. SOHLH2 overexpression promotes HR repair and radioresistance, while SOHLH2 knockdown suppresses these effects. Overexpression of RAD54L rescues the suppression of HR repair and radioresistance caused by SOHLH2 knockdown, establishing a SOHLH2→RAD54L transcriptional axis in NSCLC radioresistance.\",\n      \"method\": \"SOHLH2 knockdown and overexpression, RAD54L overexpression rescue experiments, chromatin immunoprecipitation (ChIP) for SOHLH2 binding to RAD54L promoter, HR repair assays, clonogenic survival after irradiation\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP + rescue experiment establishing epistasis; single lab with multiple functional readouts\",\n      \"pmids\": [\"41535248\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RAD54L is a SWI2/SNF2-family DNA motor protein that functions downstream of RAD51 in homologous recombination (HR): it resolves RAD51/MND1 filaments during homology search, promotes strand invasion via branch migration, and operates in at least two distinct RAD51-mediated replication fork reversal pathways (HLTF/SMARCAL1- and FBH1-dependent) with different requirements for its branch migration activity; RAD54L also plays a protective role in nucleolar rDNA surveillance, interacts physically with p53 (via the p53 C-terminus) and participates in a network of transcriptional regulation by E2F1, CHEK1, CDC7, Oct4, and SOHLH2 that modulates HR-mediated DNA repair capacity and radioresistance in cancer cells.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"RAD54L is a SWI2/SNF2-family DNA motor protein that functions as a central effector of RAD51-dependent homologous recombination (HR), participating in double-strand break repair, replication fork remodeling, and rDNA stability. It operates downstream of RAD51 to facilitate strand invasion and branch migration, defining a partially redundant HR sub-pathway alongside RAD51AP1, with RAD54B providing additional compensatory activity [PMID:35652094]. RAD54L also acts as a replication fork remodeler that restrains fork progression and catalyzes fork reversal through two mechanistically distinct RAD51-dependent pathways—one downstream of HLTF/SMARCAL1 (branch-migration-independent) and one cooperating with FBH1 (branch-migration-dependent)—and its loss prevents nascent strand degradation in BRCA1/2-deficient cells [PMID:39315725]. RAD54L directly binds p53 and colocalizes with RAD51 at DNA damage sites, placing it within a p53-regulated recombination axis, and its expression is transcriptionally controlled by E2F1, CHEK1, CDC7, Oct4, and SOHLH2 to modulate HR capacity and radiation resistance [PMID:12750285, PMID:33261027, PMID:29287241].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing that RAD54L-dependent HR and DNA-PK-dependent NHEJ constitute two independent DSB repair pathways in mammalian cells resolved whether these pathways were redundant or epistatic, showing HR as a secondary pathway when NHEJ is functional.\",\n      \"evidence\": \"Dominant-negative hRAD54 expression in DNA-PK-deficient SCID cells with clonogenic survival, comet assay, and chromosome aberration analysis\",\n      \"pmids\": [\"11289143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RAD54L catalytic activity or protein scaffolding mediates the HR contribution was not dissected\", \"No biochemical characterization of the dominant-negative mechanism\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrating that p53 directly binds RAD54L and forms a ternary complex with RAD51 at DNA damage sites revealed how p53's antirecombinogenic activity is channeled through the RAD51/RAD54L recombination machinery.\",\n      \"evidence\": \"In vitro direct binding assay, co-immunoprecipitation, colocalization by immunofluorescence, host cell reactivation recombination assay\",\n      \"pmids\": [\"12750285\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p53 binding inhibits RAD54L's ATPase/translocase activity was not tested\", \"Structural basis of the p53–RAD54L interaction remains undefined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showing that RAD54L-dependent HR contributes to telomere length regulation in SCID cells extended RAD54L's functional repertoire beyond canonical DSB repair to telomere maintenance.\",\n      \"evidence\": \"Dominant-negative hRAD54 in SCID cells, CO-FISH for telomere recombination, telomere length measurement\",\n      \"pmids\": [\"15975611\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell system (SCID) limits generalizability\", \"Whether RAD54L acts at telomeres in normal NHEJ-proficient cells was not established\", \"No direct measurement of ALT-like recombination events\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of CHEK1 and subsequently CDC7 as transcriptional regulators of RAD54L via its promoter established that upstream DNA damage checkpoint kinases control HR capacity through RAD54L expression levels, with functional consequences for radioresistance.\",\n      \"evidence\": \"siRNA knockdown, RAD54L promoter-luciferase reporter assay, clonogenic survival after irradiation, in vivo xenograft (CDC7)\",\n      \"pmids\": [\"29287241\", \"29413763\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CHEK1/CDC7 directly bind the RAD54L promoter or act through intermediate transcription factors was not determined\", \"Findings limited to glioblastoma models\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating that E2F1 directly binds the RAD54L promoter and drives its transcription linked cell-cycle-regulated transcription factor activity to HR repair capacity in bladder cancer.\",\n      \"evidence\": \"ChIP assay for E2F1 at RAD54L promoter, luciferase reporter, siRNA knockdown, γ-H2AX foci after MMC\",\n      \"pmids\": [\"33261027\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether E2F1-mediated regulation of RAD54L is cell-type-general or cancer-specific\", \"No assessment of E2F family member redundancy\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linking Oct4A-driven RAD54L expression to both HR repair and cancer stem cell self-renewal revealed a transcriptional axis connecting pluripotency factors to DNA repair proficiency and radioresistance.\",\n      \"evidence\": \"siRNA/shRNA knockdown of Oct4A and RAD54L, clonogenic survival, sphere-formation assay, olaparib radiosensitization in HNSCC\",\n      \"pmids\": [\"34079088\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Oct4A directly binds the RAD54L promoter was not shown by ChIP\", \"Synthetic lethality with PARP inhibition not tested in vivo\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Genetic epistasis revealed that RAD54L and RAD51AP1 define two distinct, partially redundant RAD51-dependent HR sub-pathways, with RAD54B providing compensatory activity for RAD54L loss, clarifying the architecture of downstream RAD51 effector pathways.\",\n      \"evidence\": \"CRISPR/siRNA double-knockout in human cancer cell lines, clonogenic survival with olaparib, MMC, and hydroxyurea\",\n      \"pmids\": [\"35652094\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical basis for why the two sub-pathways are non-redundant is unknown\", \"Whether the sub-pathways differ in D-loop stability or repair fidelity was not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Establishing RAD54L as a replication fork remodeler operating in two mechanistically distinct RAD51-mediated fork reversal pathways—one branch-migration-independent (HLTF/SMARCAL1) and one branch-migration-dependent (FBH1)—fundamentally expanded its role from DSB repair to replication stress response.\",\n      \"evidence\": \"RAD54L knockdown/knockout, DNA fiber assay, S1 nuclease assay, branch-migration-dead mutant rescue, epistasis with HLTF/SMARCAL1/FBH1\",\n      \"pmids\": [\"39315725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How RAD54L is recruited to stalled forks versus DSBs is unknown\", \"Whether the two fork reversal pathways produce structurally different reversed forks was not resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovering that RAD54L loss increases nucleolar R-loops and rDNA damage identified a novel role for RAD54L in nucleolar genome surveillance beyond canonical HR at chromosomal DSBs.\",\n      \"evidence\": \"CRISPR KO synthetic lethal screen with RNA Pol I inhibitors, R-loop immunofluorescence, nucleolar structure imaging (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.01.20.633984\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint not yet peer-reviewed\", \"Whether RAD54L resolves R-loops directly via its translocase activity or indirectly was not distinguished\", \"Relationship to rDNA copy number regulation not examined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Live-cell visualization showed RAD54L is required for dissolution of RAD51/MND1 filamentous structures during homology search, providing direct in vivo evidence for its role in completing strand invasion.\",\n      \"evidence\": \"Live-cell imaging of GFP-MND1 filaments, RAD54L knockdown/knockout, time-lapse microscopy (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.03.01.640932\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint not yet peer-reviewed\", \"Whether filament dissolution requires RAD54L ATPase activity was not tested\", \"Relationship between filament resolution and D-loop formation not directly measured\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"SOHLH2 was identified as another transcriptional activator of RAD54L, with rescue experiments confirming that RAD54L is the critical downstream effector mediating HR repair and radioresistance in NSCLC.\",\n      \"evidence\": \"SOHLH2 ChIP/luciferase at RAD54L promoter, RAD54L overexpression rescue of SOHLH2-KD phenotype, γ-H2AX foci, clonogenic survival\",\n      \"pmids\": [\"41535248\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cancer type (NSCLC)\", \"Whether SOHLH2 regulates RAD54L in normal tissue or germline is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: how RAD54L is differentially recruited to DSBs versus stalled replication forks versus rDNA loci; the structural basis for its interactions with RAD51 and p53; whether its translocase and branch migration activities are independently regulated in vivo; and what distinguishes the functional contributions of RAD54L from RAD54B in different genomic contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of RAD54L in complex with RAD51 or p53\", \"Mechanism of context-dependent pathway choice (fork reversal vs. DSB repair vs. rDNA surveillance) unknown\", \"In vivo post-translational regulation of RAD54L enzymatic activities not characterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [4, 10]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 10]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 1, 3, 4, 5]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [4, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"RAD51\",\n      \"TP53\",\n      \"RAD51AP1\",\n      \"RAD54B\",\n      \"FBH1\",\n      \"HLTF\",\n      \"SMARCAL1\",\n      \"MND1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"RAD54L is a SWI2/SNF2-family ATPase that functions downstream of RAD51 in homologous recombination, where it resolves RAD51/MND1-containing filaments during homology search, promotes strand invasion, and operates in two distinct RAD51-dependent replication fork reversal pathways—one HLTF/SMARCAL1-dependent (branch migration-dispensable) and one FBH1-dependent (branch migration-essential)—to restrain fork progression and suppress replication-associated ssDNA gaps [PMID:39315725, PMID:35652094]. RAD54L defines a non-redundant HR sub-pathway parallel to RAD51AP1, and its loss synergistically sensitizes cells to PARP inhibitors, mitomycin C, and hydroxyurea [PMID:35652094]. RAD54L physically interacts with p53 via the p53 C-terminus and co-localizes with RAD51 at DNA damage sites, integrating HR with p53-mediated anti-recombinogenic control [PMID:12750285]. Its expression is transcriptionally regulated by E2F1, CHEK1, CDC7, Oct4, and SOHLH2, linking HR repair capacity to radioresistance in multiple cancer types [PMID:33261027, PMID:29287241, PMID:41535248].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"The question of whether RAD54L-dependent HR contributes to DSB repair in mammalian cells was addressed by showing that dominant-negative RAD54L increases radiation sensitivity and chromosomal aberrations only when the primary NHEJ pathway (DNA-PKcs) is inactivated, establishing HR as a backup DSB repair route whose contribution is masked by NHEJ.\",\n      \"evidence\": \"Dominant-negative hRAD54 expression in SCID (DNA-PK-deficient) cells with IR sensitivity, PFGE, and chromosome aberration analysis\",\n      \"pmids\": [\"11289143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RAD54L enzymatic activity (ATPase/branch migration) is specifically required was not dissected\", \"Contribution of RAD54L to HR in non-transformed human cells was not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The nature of RAD54L's interaction with p53 and RAD51 was clarified: RAD54L co-immunoprecipitates with both p53 and RAD51 at endogenous levels, binds p53's C-terminus directly in vitro, and co-localizes at DNA processing sites, placing RAD54L within the p53-regulated HR complex.\",\n      \"evidence\": \"Co-IP, GST pulldown for direct binding, immunofluorescence co-localization, and host-cell reactivation recombination assay in human cells\",\n      \"pmids\": [\"12750285\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the p53–RAD54L interaction is unknown\", \"Functional consequence of disrupting the p53–RAD54L interaction specifically (vs. p53–RAD51) was not separated\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"RAD54L-dependent HR was shown to mediate the aberrant telomere elongation observed in SCID cells, extending RAD54L's functional scope beyond canonical DSB repair to telomere maintenance.\",\n      \"evidence\": \"Dominant-negative RAD54L in SCID cells with telomere length measurement and CO-FISH for telomeric recombination\",\n      \"pmids\": [\"15975611\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether RAD54L acts at telomeres in wild-type cells with functional DNA-PKcs is unknown\", \"Mechanism by which HR elongates telomeres in SCID cells was not molecularly resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Beyond its repair role, RAD54L was identified as a potential oncogene gained in choroid plexus carcinoma, with functional knockdown demonstrating its requirement for CPC initiation and progression—expanding RAD54L's disease relevance beyond DNA repair deficiency.\",\n      \"evidence\": \"Cross-species syntenic genome analysis plus functional knockdown in mouse CPC model and human CPC cell lines\",\n      \"pmids\": [\"25965574\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which RAD54L promotes tumorigenesis (repair-dependent vs. repair-independent) was not resolved\", \"Whether this oncogenic role extends to other tumor types was not determined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Upstream transcriptional control of RAD54L began to be mapped: CHEK1 and subsequently CDC7 were shown to regulate RAD54L promoter activity in glioblastoma, establishing kinase-to-transcription axes that modulate HR capacity and radioresistance.\",\n      \"evidence\": \"siRNA knockdown of CHEK1/CDC7, luciferase reporter assays for RAD54L promoter, clonogenic survival after IR, xenograft models\",\n      \"pmids\": [\"29287241\", \"29413763\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CHEK1 and CDC7 act on the same or distinct cis-elements in the RAD54L promoter is unknown\", \"Direct transcription factor intermediaries between these kinases and the RAD54L promoter were not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"E2F1 was shown to directly bind the RAD54L promoter and transcriptionally induce RAD54L expression, with the resulting RAD54L mediating HR repair of mitomycin C-induced DSBs in bladder cancer, providing the first direct transcription factor–promoter interaction driving RAD54L in cancer.\",\n      \"evidence\": \"ChIP for E2F1 at RAD54L promoter, siRNA knockdown, mitomycin C DNA damage repair assays in bladder cancer cells\",\n      \"pmids\": [\"33261027\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether E2F1 is the dominant transcriptional regulator of RAD54L or cooperates with CHEK1/CDC7-regulated factors is unclear\", \"Chromatin context and epigenetic modulation of the RAD54L promoter were not examined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Genetic epistasis analysis using CRISPR double knockouts established that RAD54L and RAD51AP1 define two parallel, non-redundant HR sub-pathways downstream of RAD51, with concomitant loss producing synergistic sensitivity to olaparib, mitomycin C, and hydroxyurea.\",\n      \"evidence\": \"CRISPR/Cas9 double KO of RAD51AP1 and RAD54L in human cancer cells, multi-agent drug sensitivity assays\",\n      \"pmids\": [\"35652094\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate or intermediate specificity distinguishing the two sub-pathways is not defined\", \"Whether RAD54B fully substitutes for RAD54L in specific genomic contexts was not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"RAD54L was shown to function as a replication fork remodeler that restrains fork progression and suppresses ssDNA gaps under replication stress, acting in two mechanistically distinct RAD51-mediated fork reversal pathways—one with HLTF/SMARCAL1 (branch migration dispensable) and one with FBH1 (branch migration essential)—resolving a longstanding question about how RAD54L's ATPase and branch migration activities are differentially deployed.\",\n      \"evidence\": \"DNA fiber assays, genetic epistasis with HLTF/SMARCAL1/FBH1 KO, branch migration-deficient RAD54L mutant, nascent strand degradation in BRCA1/2- and 53BP1-deficient backgrounds\",\n      \"pmids\": [\"39315725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for differential engagement of RAD54L in the two fork reversal pathways is unknown\", \"Whether the fork remodeling function is relevant in non-replicating or quiescent cells was not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Live-cell imaging directly visualized RAD54L's requirement for resolution of RAD51/MND1-containing filaments during homology search, placing RAD54L at the transition from homology search to strand invasion in living human cells.\",\n      \"evidence\": \"Live-cell imaging with GFP-MND1, RAD54L siRNA/knockout, time-lapse microscopy of filament dynamics (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.03.01.640932\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether RAD54L's ATPase or branch migration activity drives filament resolution is not distinguished\", \"Awaits peer review and independent replication\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A CRISPR synthetic lethal screen revealed an unexpected protective role for RAD54L in nucleolar rDNA surveillance: RAD54L loss increases nucleolar R-loops, rDNA damage, and sensitivity to PARP and RNA Pol I inhibitors, extending RAD54L function to the nucleolar DNA damage response.\",\n      \"evidence\": \"CRISPR-Cas9 screen with RNA Pol I inhibitors, RAD54L KO, DRIP for R-loops, rDNA damage and nucleolar structure assays (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.01.20.633984\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether RAD54L acts directly on rDNA or indirectly via general HR at the nucleolus is unclear\", \"Awaits peer review and independent validation\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"SOHLH2 was identified as a transcriptional activator of RAD54L in NSCLC, with RAD54L overexpression fully rescuing HR repair and radioresistance upon SOHLH2 loss, confirming a direct SOHLH2→RAD54L transcriptional axis.\",\n      \"evidence\": \"ChIP for SOHLH2 at RAD54L promoter, rescue overexpression experiments, HR repair and clonogenic survival assays\",\n      \"pmids\": [\"41535248\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether SOHLH2 cooperates with E2F1 or other transcription factors at the RAD54L promoter is unknown\", \"Relevance of the SOHLH2–RAD54L axis in non-malignant tissues is not examined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis for RAD54L's differential engagement in fork reversal vs. DSB repair vs. nucleolar rDNA surveillance; whether RAD54L's repair-independent oncogenic function in CPC and other tumors depends on its ATPase/branch migration activities; and how the multiple transcriptional inputs (E2F1, CHEK1, CDC7, Oct4, SOHLH2) are integrated at the RAD54L promoter in physiological contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of human RAD54L in complex with its substrates or partners\", \"Repair-dependent vs. repair-independent oncogenic mechanisms not separated\", \"Integrated promoter logic for RAD54L regulation across cell types not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [10, 13]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [10, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 13]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 1, 8, 10, 13]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"RAD51\",\n      \"TP53\",\n      \"RAD51AP1\",\n      \"MND1\",\n      \"HLTF\",\n      \"SMARCAL1\",\n      \"FBH1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}